These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 21314633)

  • 1. Current pharmacologic management of pediatric heart failure in congenital heart disease.
    Bautista-Hernandez V; Sanchez-Andres A; Portela F; Fynn-Thompson F
    Curr Vasc Pharmacol; 2011 Sep; 9(5):619-28. PubMed ID: 21314633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic therapy of heart failure in children: part of a special series on paediatric pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni.
    Timberlake K; Kantor PF
    Pharmacol Res; 2011 Nov; 64(5):427-30. PubMed ID: 21708258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New therapies for heart failure.
    Riggs JM
    RN; 2004 Mar; 67(3):28-32; quiz 33. PubMed ID: 15065491
    [No Abstract]   [Full Text] [Related]  

  • 4. Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Chronic Heart Failure.
    Rossano JW; Cabrera AG; Jefferies JL; Naim MP; Humlicek T
    Pediatr Crit Care Med; 2016 Mar; 17(3 Suppl 1):S20-34. PubMed ID: 26945326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levosimendan use in several scenarios of acute heart failure.
    Tavares M; Andrade AC; Mebazaa A
    Arq Bras Cardiol; 2008 Mar; 90(3):211-5. PubMed ID: 18392402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of noninvasive hemodynamics to aid decision making in the initiation and titration of neurohormonal agents.
    Summers RL; Parrott CW; Quale C; Lewis DL
    Congest Heart Fail; 2004; 10(2 Suppl 2):28-31. PubMed ID: 15073483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical therapy in heart failure--is polypharmacy necessary?
    Kwok BW
    Ann Acad Med Singap; 2004 Jul; 33(4):444-50. PubMed ID: 15329755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applying standard therapies to new targets: the use of ACE inhibitors and B-blockers for heart failure in adults with congenital heart disease.
    Vonder Muhll I; Liu P; Webb G
    Int J Cardiol; 2004 Dec; 97 Suppl 1():25-33. PubMed ID: 15590076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natriuretic peptide-guided levosimendan therapy for heart failure: a promising new approach.
    Giamouzis G; Giannakoulas G; Tsarpalis K; Agha SA; Georgiopoulou V; Kalogeropoulos A; Karvounis H; Butler J
    Int J Cardiol; 2008 Aug; 128(1):91-3; author reply 94-6. PubMed ID: 18495268
    [No Abstract]   [Full Text] [Related]  

  • 10. Perioperative cardiac evaluation: the importance of cardiac failure management.
    Markogiannakis H; Kapralou A; Toufektzian L; Theodorou D; Katsaragakis S
    South Med J; 2008 Jun; 101(6):661-2. PubMed ID: 18528222
    [No Abstract]   [Full Text] [Related]  

  • 11. Congestive heart failure in pediatric patients.
    Kay JD; Colan SD; Graham TP
    Am Heart J; 2001 Nov; 142(5):923-8. PubMed ID: 11685182
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of the recombinant form of the natural human B-type natriuretic peptide and levosimendan on pulmonary hyperventilation and chemosensivity in heart failure.
    Bocchi EA; Moura LZ; Issa VS; Cruz F; Carvalho VO; Guimarães GV
    Cardiovasc Ther; 2013 Apr; 31(2):100-7. PubMed ID: 21884030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapies for heart failure: a report from the Heart Failure Congress 2007.
    Rabasseda X
    Timely Top Med Cardiovasc Dis; 2007 Jul; 11():E16. PubMed ID: 18297144
    [No Abstract]   [Full Text] [Related]  

  • 14. Medical treatment of end-stage heart failure.
    Binetti G; Senni M; Colombo F; Tasca G; Mamprin F; Caporale R; Ferrazzi P; Gamba A; Glauber M; Troise G; Fiocchi R
    Cardiovasc Drugs Ther; 1996 Nov; 10 Suppl 2():617-22. PubMed ID: 9115955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Levosimendan: a new option in the pharmacologic management of cardiac insufficiency].
    Del-Razo OE; Carballal-Sanjurjo JC; Campos Lara MG; Palma-Aguirre JA
    Gac Med Mex; 2003; 139(1):87-9. PubMed ID: 12666417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical therapy in adults with congenital heart disease.
    Book WM; Shaddy RE
    Heart Fail Clin; 2014 Jan; 10(1):167-78. PubMed ID: 24275302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can we believe in levosimendan?
    Follath F
    Arq Bras Cardiol; 2008 Mar; 90(3):146-7. PubMed ID: 18392391
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel biologic mechanisms of levosimendan and its effect on the failing heart.
    Parissis JT; Andreadou I; Bistola V; Paraskevaidis I; Filippatos G; Kremastinos DT
    Expert Opin Investig Drugs; 2008 Aug; 17(8):1143-50. PubMed ID: 18616411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermittent levosimendan infusions in advanced heart failure: favourable effects on left ventricular function, neurohormonal balance, and one-year survival.
    Malfatto G; Della Rosa F; Villani A; Rella V; Branzi G; Facchini M; Parati G
    J Cardiovasc Pharmacol; 2012 Nov; 60(5):450-5. PubMed ID: 22932705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rational diagnostics and current treatment concepts in the management of chronic heart failure].
    Weil J
    Med Klin (Munich); 2008 Sep; 103(9):646-62; quiz 663-4. PubMed ID: 18813888
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.